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Abstract
Background: Cost-effectiveness is an increasingly important factor in the choice of a test or therapy.
Objective: To assess the cost-effectiveness of various methods routinely used for the diagnosis of stable coronary disease 
in Portugal.
Methods: Seven diagnostic strategies were assessed. The cost-effectiveness of each strategy was defined as the cost 
per correct diagnosis (inclusion or exclusion of obstructive coronary artery disease) in a symptomatic patient. The cost 
and effectiveness of each method were assessed using Bayesian inference and decision-making tree analyses, with the 
pretest likelihood of disease ranging from 10% to 90%.
Results: The cost-effectiveness of diagnostic strategies was strongly dependent on the pretest likelihood of disease. 
In patients with a pretest likelihood of disease of ≤50%, the diagnostic algorithms, which include cardiac computed 
tomography angiography, were the most cost-effective. In these patients, depending on the pretest likelihood of 
disease and the willingness to pay for an additional correct diagnosis, computed tomography angiography may be 
used as a frontline test or reserved for patients with positive/inconclusive ergometric test results or a calcium score 
of >0. In patients with a pretest likelihood of disease of ≥ 60%, up-front invasive coronary angiography appears to 
be the most cost-effective strategy.
Conclusions: Diagnostic algorithms that include cardiac computed tomography angiography are the most cost-effective 
in symptomatic patients with suspected stable coronary artery disease and a pretest likelihood of disease of ≤50%. 
In high-risk patients (pretest likelihood of disease ≥ 60%), up-front invasive coronary angiography appears to be the most 
cost-effective strategy. In all pretest likelihoods of disease, strategies based on ischemia appear to be more expensive and 
less effective compared with those based on anatomical tests. (Arq Bras Cardiol. 2014; 102(4):391-402)
Keywords: Coronary disease / economics; Coronary disease / diagnosis; Cost-Benefit analysis.
Introduction
Clinical assessment of an individual with suspected stable 
coronary artery disease (CAD) is usually complemented by 
noninvasive tests such as the ergometric test (ET), myocardial 
perfusion scintigraphy (MPS), or stress echocardiography 
(StressEcho). Cardiac computed tomography angiography 
(CCTA) has broadened the options for the assessment of 
CAD patients and is a potentially beneficial alternative for 
individuals with an intermediate or a low pretest likelihood 
of disease (PLD)1. However, the generalized adoption of new 
techniques that, although appealing, may entail additional 
costs and no added value, should be considered carefully 
with regard to the increasing economic pressure to which 
healthcare systems are exposed. Therefore, it is important 
to determine the cost-effectiveness of diagnostic strategies 
routinely used for the diagnosis of stable CAD and identify 
patients for whom CCTA is a cost-effective alternative.
Methods
The cost-effectiveness of seven diagnostic strategies was 
assessed: (1) ET followed by MPS in positive or inconclusive 
cases, (2) ET followed by 64-detector CCTA in positive or 
inconclusive cases, (3) MPS (as first option), (4) StressEcho 
with dobutamine (as first option), (5) CCTA (as first option), 
(6) calcium scoring (CaSc) followed by CCTA (CACS-CCTA) 
when CaSc > 0, and (7) invasive coronary angiography 
(CATH) as the first and only test. All considered strategies 
presuppose the end of the diagnostic procedures when a test 
is negative and a confirmation CATH when the last test of the 
noninvasive strategy is positive or inconclusive. In addition, 
an eight alternative was assessed in individuals with a PLD 
of 10%, which involved not performing any complementary 
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Table 1 – Sensitivity, specificity, and rate of nondiagnostic tests for each method as assumed in the economic model
ET (%) MPS (%) StressEcho (%) CCTA (%) CACS > 0 (%)
Sensitivity 687 878,9 8610 984 935,6
Specificity 777 8111 8410 854 435,6
Rate of nondiagnostic tests 1712 0 1813 04 0
ET: ergometric test; MPS: myocardial perfusion scintigraphy; StresEco: stress echocardiogram with dobutamine; CCTA: computed tomography angiography of the 
coronary arteries; CaSc: calcium scoring
A decision-making tree analysis was performed according 
to the method described by Patterson et al2,3 to assess the 
cost-effectiveness of each strategy according to PLD. In this 
method, hypothetical cohorts of patients with a certain PLD are 
subjected to each of the diagnostic strategies. Then, Bayesian 
inference is used to estimate the cost and effectiveness of 
each strategy according to the test characteristics. Sensitivity, 
specificity, and the rate of nondiagnostic tests were gathered 
from meta-analysis, clinical recommendations, and published 
series (Table 1). The rate of nondiagnostic ET and StressEcho 
tests was calculated as the mean percentage of patients who 
fail to reach the target heart rate. MPS was always considered 
to be diagnostic, and its accuracy was considered independent 
of the stress method used. In addition, CCTA tests were always 
considered diagnostic since the meta-analysis on its accuracy 
was performed on an intention-to-diagnose basis, assuming 
that all nondiagnostic tests would be false-positive, thereby 
decreasing the specificity of the test4. The sensitivity and 
specificity of CaSc > 0 for the diagnosis of obstructive CAD 
were obtained through combined analysis of the results of two 
international multicenter clinical trials5,6. We assumed that 
CATH tests would always be diagnostic, with a sensitivity and 
specificity of 100%.
Comparison of cost-effectiveness
The cost-effectiveness of each strategy was defined as 
the cost per correct diagnosis (inclusion or exclusion of 
obstructive CAD) in a symptomatic patient. According to 
this definition, a lower cost value per correct diagnosis 
translates into better cost-effectiveness. Comparison 
between the diagnostic strategies was made from the 
society’s perspective (i.e., including all costs, regardless of 
the payer)14. To compare the incremental cost-effectiveness 
of each option with that of all the other alternatives, the 
diagnostic strategies were ranked in increasing order of 
cost and those outperformed by complete dominance 
(simultaneously more expensive and less effective) and 
incomplete dominance (less effective with a higher 
incremental cost-effectiveness ratio; ICER) were excluded. 
ICERs (added cost per additional correct diagnosis) were 
calculated for each strategy relative to the previous less 
expensive strategy.
Definition of cost
The cost of a diagnostic strategy includes direct and 
indirect costs. Direct cost was considered as the cost of 
the examinations performed for patients in each cohort, 
using the current Tabela de Preços do Serviço Nacional de 
Saúde (price list of the National Health Service), which was 
defined by the Ordinance 839-A/2009 of July 31, 2009, 
as a reference15. The price of cardiac CCTA was defined 
as the sum of the values of CCTA, intravenous contrast 
supplement, and post-processing (Table 2). In the CaSc-
CCTA strategy, a cost of € 80.00 was assumed (identical 
to that of noncontrast chest CT)15 for patients who only 
underwent CaSc, while a cost of € 207.10 was assumed 
for those who also underwent CCTA.
Table 2 – Price of tests included in the different diagnostic strategies (values for Portugal)
Code15 Designation Price (€)
40315 Stress test in ergometric bicycle or treadmill with continuous ECG monitoring and recording at each stage 36.80
58015 Myocardial perfusion scintigraphy under pharmacological stress 424.40
40660 Transthoracic echocardiography under pharmacological stress (includes the cost of the drug) 121.80
16350 CCTA (129.40)
16325 CT, intravenous contrast supplement (62.60)
16345 Post-processing (15.10)
- Total cardiac CCTA (three codes) 207.10
- Calcium scoring 80.00
40820 Left catheterization with selective coronary angiography 585.50
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The following indirect costs were included.
1. Cost associated with incidental findings during CaSc and 
cardiac CCTA. We assumed that 7% of these tests would exhibit 
incidental extracardiac findings of uncertain clinical significance, 
which would require direct investigation16, usually to assess lung 
nodules. We assumed that these cases would require noncontrast 
chest CT a few months later17 at an additional cost of € 80.0015.
2. Cost associated with complications caused by diagnostic 
CATH. We assumed that the rate of major iatrogenic adverse 
cardiovascular events (death, myocardial infarction, or stroke) 
was 0.05%18, while that of vascular access-related complications 
that required transfusion or surgery was 0.4% (for a rate of 80% 
for radial access use)19. With regard to major cardiovascular 
events, we considered acute myocardial infarction to be a typical 
complication3,20 and estimated its cost by adding the cost for a 
homogeneous diagnostic group (HDG) of patients with nonfatal 
myocardial infarction without major complications (€3,671.53)15 
to the cost of 1 month of temporary incapacity to work, for a gross 
domestic product (GDP) per capita of €16,100, assuming that half 
of the population assessed for suspected CAD was active. The mean 
cost of an iatrogenic major cardiovascular event thus estimated was 
€ 4,342. The mean cost of a vascular access complication requiring 
transfusion or surgery was estimated to be €1,500 (expert opinion).
3. Cost of false-negative tests. The potential cost of 
false-negative tests includes the cost of repeat tests for 
CAD diagnosis, other examinations for the differential 
diagnosis of chest pain, worse quality of life, and added 
risk for cardiovascular events due to the non-prescription of 
adequate medical therapy. These costs are particularly difficult 
to evaluate. Previous studies have used various methods 
to estimate that the cost of a false-negative test is 1.4–6.7 
times higher than that of a false-positive test3,20,21. Therefore, 
false-negative tests were allocated a cost that was three times 
higher than that of a false-positive test (€1.818 for each 
false-negative test). In the scenario where no further testing 
is performed assuming the absence of CAD (a hypothesis 
considered for patients with PLD of 10%), the costs of 
false-negatives were the only ones taken into account.
We did not include the cost of complications caused by 
noninvasive tests in the model because serious complications 
resulting from these tests are very rare and would only 
marginally increase costs. In addition, the cost associated 
with potential exposure to ionizing radiation was not included 
because this was a short-term cost-effectiveness model; 
furthermore, there is great uncertainty about the effects of 
radiation doses used in these tests22.
Sensitivity analysis
To assess the extent to which the results obtained depended 
on some of the variables under study, several sensitivity 
analyses were performed. Calculations were repeated 
using new assumptions such as decreasing the sensitivity 
and specificity values for cardiac CCTA to 96% and 81%, 
respectively (lower limits of 95% confidence intervals in the 
meta-analysis of 53 studies)4, decreasing the cost of MPS 
to €207.10 (equating the cost of MPS with that of CCTA), 
decreasing the rate of inconclusive StressEcho tests to 5%, 
and assuming zero cost for false-negative tests. 
Results
Figure 1 shows the cost-effectiveness plans for the 
diagnostic strategies for each scenario of PLD. In general, costs 
increase and the percentage of correct diagnosis decreases 
with increasing PLD (due to the increase in the number of 
false-negative tests).
The composition of direct and indirect costs is shown in 
Table 3 (simulation of the expected results when a cohort of 
100 patients with a PPT of 30% is assessed).
Table 4 summarizes the results of incremental 
cost-effectiveness of the diagnostic strategies applied to 
hypothetical cohorts of 100 patients with a PLD of 10%–90%. 
Diagnostic strategies were presented in increasing order of cost 
and respective ICER for each assessed PLD. In all scenarios of 
PLD, the diagnostic strategies for ET-MPS, MPS, and StressEcho 
are dominated by alternative strategies that are less expensive 
and more effective. According to the cost-effectiveness 
criterion, choosing the best diagnostic strategy depends on the 
percentage of false-negative tests that one is willing to accept 
and on the willingness to pay for an additional correct diagnosis 
(Figure 2). For example, for a limit of €5,000 per additional 
correct diagnosis, the preferred strategy would be CACS-CCTA 
for patients with a PLD of 10%, CCTA for those with a PLD of 
20%–40%, and CATH for those with a PLD of ≥50%.
Results of sensitivity analysis 
To assess the robustness of the results and the influence 
of several assumptions, we reformulated the model by 
altering some parameters such as diagnostic accuracy of 
CCTA, price of MPS, rate of inconclusive StressEcho tests, 
and cost of false-negative tests.
The decrease in sensitivity and specificity of CCTA to 96% and 
81%, respectively, resulted in the increase in total cost and ICER 
of the strategies that include CCTA. Nevertheless, the ET-MPS, 
MPS, and StressEcho diagnostic strategies remained dominated, 
with the increasing order of cost-effectiveness shown in Table 4 
being maintained for every assessed PLD.
When the cost of MPS is equated to the cost of CCTA 
(€ 207.10), the cost-effectiveness of the ET-MPS and MPS 
diagnostic strategies improves. However, these strategies 
remained dominated by other diagnostic methods (less 
expensive and more effective) for all assessed PLDs (Table 5). 
The decrease in the rate of inconclusive StressEcho tests from 
18% to 5% resulted in the improvement of its cost-effectiveness; 
however, this method remained dominated by other diagnostic 
strategies for all the assessed PLDs. When the StressEcho strategy 
was compared with the dominant noninvasive strategies (more 
cost-effective), at each level of PLD, the StressEcho strategy 
entailed an additional cost of €303 to €2,700 per 100 patients, 
along with an increase in false-negative tests from 1.1% to 5.7%.
In the model where the absence of indirect costs is assumed 
in patients with false-negative tests, the ET-CCTA strategy is the 
least expensive for all levels of PLD. However, this diagnostic 
procedure resulted in a significant number of false-negative 
tests, particularly for intermediate or high PLDs. The transition 
to more effective strategies becomes less expensive with the 
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Figure 1 – Cost-effectiveness plans for the diagnostic strategies according to the pretest likelihood of disease.
Discussion
In recent years, the need to consider the cost of 
clinical decisions is becoming increasingly important. 
Cost-effectiveness analyses allow for more efficient use of 
health resources and rationalize the use of new technologies, 
often more expensive than their alternatives. To our 
knowledge, this is the first assessment of the cost-effectiveness 
of several strategies used for the diagnosis of stable CAD 
in Portugal. The results of this analysis indicate that, in this 
country, diagnostic algorithms that include cardiac CCTA are 
the most cost-effective methods in symptomatic patients with 
suspected obstructive CAD and a PLD of ≤50%. In high-risk 
patients (PLD > 50%), immediate CATH appears to be the 
most cost-effective strategy. The model suggests that ischemia 
imaging techniques (MPS and StressEcho) are more expensive 
and less effective compared with other diagnostic strategies for 
all assessed PLDs. With regard to patients with a PLD of ≤50% 
and the conservative scenario wherein the willingness to pay 
for an additional correct diagnosis is €1.000, the results of 
incremental cost-effectiveness indicate that it is advantageous 
to perform an ergometric test before CCTA in patients with 
a lower PLD (10%), do a “rule-out” CaSc before CCTA in 
patients with a PLD of 20-30%, and perform up-front CCTA 
in patients with a PLD of 40-50%. In the more liberal scenario 
(willingness to pay €5.000 for an additional correct diagnosis), 
the preferred strategy would be SCa-CCTA for patients with a 
PLD of 10%, CCTA for patients with a PLD of 20%–40%, and 
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Table 3 – Results of cost-effectiveness of the diagnostic strategies for 100 patients with a pretest likelihood of disease of 30%
ET-MPS ET-CCTA MPS StressEcho CCTA CACS-CCTA CATH
After non-invasive testing
True positive 19.2 21.6 26.1 21.2 29.4 27.4 -
False positive 4.8 3.8 13.3 9.2 10.5 6.0 -
True negative 65.2 66.2 56.7 48.2 59.5 64.0 -
False negative 10.8 8.4 3.9 3.4 0.6 2.6 -
Inconclusive 0 0 0 18 0 0 -
Invasive Angiographies 24 25.4 39.4 48.4 39.9 33.4 100
Normal invasive Angiographies 4.8 (20%) 3.8 (15%) 13.3 (34%) 21.8 (45%) 10.5 (26%) 6 (18%) 70 (70%)
Correct diagnoses
(after CATH when applicable) 89.2 91.6 96.1 96.6 99.4 97.4 100
Costs
Noninvasive tests € 23.752 € 13.475 € 42.440 € 12.180 € 20.710 € 16.642 -
CATH € 14.033 € 14.860 € 23.069 € 28.303 € 23.362 € 19.543 € 58.550
CATH complications de CATH € 318 € 337 € 523 € 643 € 530 € 443 € 1.327
Incidental findings - € 265 - - € 560 € 560 -
False-negative tests € 19.693 € 15.287 € 7.090 € 6.261 € 1.091 € 4.785 -
Total cost € 57.796 € 44.224 € 73.122 € 47.386 € 46.252 € 41.973 € 59.877
Cost per correct diagnosis € 648 € 483 € 761 € 491 € 465 € 431 € 599
ET: ergometric test, MPS: myocardial perfusion scintigraphy, CCTA: computed tomography angiography of the coronary arteries, StressEcho: stress echocardiography 
with dobutamine, CACS: calcium score, CATH: invasive coronary angiography
Ultimately, the selection of a diagnostic method on the 
basis of cost-effectiveness criteria depends on PLD and 
the willingness to pay for an additional correct diagnosis. 
Contrary to long-term cost-effectiveness studies, in this 
context, there is no commonly accepted cost-effectiveness 
limit [for example: € 30,000/quality-adjusted life-years 
(QALY)] to serve as a reference for the adoption or rejection 
of a diagnostic strategy. However, a recent study suggested 
that, for a CAD prevalence of ≥30%, values of incremental 
cost per correct diagnosis in the short-term model are similar 
to those of incremental cost per QALY estimated in long-term 
models23. In a more conservative scenario, the willingness 
of the Portuguese society to pay for an additional correct 
diagnosis will be at least ≥ €1.010, which corresponds to 
the sum of the direct costs of MPS followed by CATH, a 
diagnostic strategy that is well accepted and frequently used 
in Portugal.
Of the scenarios assessed in the sensitivity analysis, 
the one in which CCTA and MPS have the same price is 
particularly important because this is the case in some 
countries. Even in this scenario, MPS remains a dominated 
strategy (i.e., more expensive and less effective) because it is 
less accurate than CCTA, particularly in terms of sensitivity. 
The results would only be different in a scenario (not tested) 
where the price of scintigraphy was identical and where 
scintigraphy was more accurate.
In general, these results are in line with those obtained 
in other countries17,20,24-29 that consider cardiac CCTA as 
a cost-effective method for the diagnosis or exclusion of 
obstructive CAD in patients with an intermediate PLD. 
This is probably because of a favorable combination of 
cost (relatively affordable) and accuracy. Better diagnostic 
accuracy simultaneously increases the denominator of the 
cost-effectiveness equation (number of correct diagnoses) 
and decreases the numerator, with lower indirect costs from 
false-negative and false-positive tests.
The interpretation of these results and analysis of their 
potential implications should consider several factors. First, it 
should be noted that the cost-effectiveness of diagnostic strategies 
is critically dependent on the adequate selection of patients. 
The calculation of PLD is a key step in selecting a cost-effective 
diagnostic strategy. This assessment can be easily and quickly 
made using validated clinical scores that were recently calibrated 
in European contemporary populations30. Second, the results 
of this analysis only apply to patients without known CAD. 
Therefore, these findings do not mean that functional tests are 
not useful or cost-effective in distinct contexts, namely in patients 
with established CAD. In the latter case, the performance of CCTA 
is suboptimal, and the key issues are the presence or absence of 
ischemia and the localization, extension, and severity of ischemia. 
Rather than seeing these results in terms of winners and losers, 
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Table 4 – Incremental cost-effectiveness of the diagnostic strategies applied to hypothetical cohorts of 100 patients with a PLD of 10%–60%. 
For a PLD of >=60%, all strategies are dominated by the CATH strategy.
Pretest likelihood Diagnostic strategy Total cost  (€) Number of correct diagnoses* False-negative tests* ICER**
10%
No test 18.180 90.0 10.0 -
ET-CCTA 24.473 97.2 2.8 € 874
CACS-CCTA 27.975 99.1 0.9 € 1.819
ET-MPS 34.667 96.4 3.6 Dominated
CCTA 35.585 99.8 0.2 € 11.234
StressEcho 36.338 98.9 1.1 Dominated
CATH 59.877 100 0 € 121.461
MPS 60.252 98.7 1.3 Dominated
20%
ET-CCTA 34.349 94.4 5.6 -
CACS-CCTA 34.974 98.2 1.8 € 162
CCTA 40.918 99.6 0.4 € 4.388
StressEcho 41.862 97.7 2.3 Dominated
ET-MPS 46.232 92.8 7.2 Dominated
CATH 59.877 100 0 € 47.397
MPS 66.687 97.4 2.6 Dominated
30%
CACS-CCTA 41.973 97.4 2.6 -
ET-CCTA 44.224 91.6 8.4 Dominated
CCTA 46.252 99.4 0.6 € 2.106
StressEcho 47.386 96.6 3.4 Dominated
ET-MPS 57.796 89.2 10.8 Dominated
CATH 59.877 100 0 € 22.709
MPS 73.122 96.1 3.9 Dominated
40%
CACS-CCTA 48.972 96.5 3.5 -
CCTA 51.585 99.2 0.8 € 964
StressEcho 52.910 95.4 4.6 Dominated
ET-CCTA 54.099 88.8 11.2 Dominated
CATH 59.877 100 0 € 10.365
ET-MPS 69.361 85.6 14.4 Dominated
MPS 79.557 94.8 5.2 Dominated
50%
CACS-CCTA 55.971 95.6 4.4 -
CCTA 56.919 99.0 1.0 € 280
StressEcho 58.434 94.3 6.7 Dominated
CATH 59.877 100 0 € 2.959
ET-CCTA 63.975 86.0 14.0 Dominated
ET-MPS 80.925 82.0 18.0 Dominated
MPS 85.992 93.5 6.5 Dominated
60%
CATH 59.877 100 0 -
CCTA 62.252 98.8 1.9 Dominated
CACS-CCTA 62.970 94.7 5.3 Dominated
StressEcho 63.958 93.1 6.9 Dominated
ET-CCTA 73.850 83.2 16.8 Dominated
MPS 92.427 92.2 7.8 Dominated
ET-MPS 92.490 78.3 21.7 Dominated
* At the end of the diagnostic strategy, i.e., including the results of CATH when the noninvasive tests are positive or inconclusive ** Incremental cost per additional correct 
diagnosis. ICER: incremental cost-effectiveness ratio (∆ cost/∆ correct diagnosis), ET: ergometric test, CCTA: computed tomography angiography of the coronary 
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Figure 2 – Choice of the most cost-effective diagnostic strategy according to the PLD and willingness to pay for a correct diagnosis. Once the maximum value that society 
is willing to pay for an additional correct diagnosis is established, the strategy that represents the best use of these resources is the one that intercepts the line of the value 
that society is willing to pay. For example, for a willingness to pay €1,500 per additional correct diagnosis, the best method would be ET-CCTA when the pretest likelihood 
of disease is 10%, CACS-CCTA when the pretest likelihood is 20%–30%, CCTA when the pretest likelihood is 40%–50%, and CATH when the pretest likelihood is ≥60%. 
the anatomical and functional methods in different contexts. 
Third, it should be acknowledged that the exclusive use of 
anatomical methods for the diagnosis of obstructive CAD 
carries some risks, namely the hazard of prompting unnecessary 
revascularizations. However, CATH, in the assessed strategies, had 
a diagnostic and not necessarily therapeutic objective (as in the 
COURAGE study)31, and although both coronary angiographies 
(invasive or CT) essentially provide anatomical information, there 
is a possibility of complementing this assessment with functional 
information provided by coronary fraction flow reserve (FFR) 
measurement, which is emerging as the gold-standard and has 
been demonstrated to be cost-effective32. It is probable that, 
in the near future, CCTA will allow the assessment of ischemia 
using perfusion techniques33 or virtual CFR measurements34,35; 
however, this is not yet an established procedure.
Limitations
This study has some limitations. First, it described a theoretical 
model, the results of which are dependent on factors such as 
sensitivity and specificity of various techniques that, in the real 
world, can be different from those reported in international 
studies of reference. With regard to CCTA, it should be noted that 
its specificity depends on PLD because of the varying prevalence 
of coronary calcifications. The use of intermediate values may 
have led to the underestimation of the cost-effectiveness of CCTA 
in patients with a lower PLD and overestimation in patients 
with a higher PLD36. Similarly, like in all analyses of this type, 
the results are only applicable to patients who are capable of 
undergoing any of the tests under study (i.e., able to exercise, 
without complete block of the left bundle branch, without severe 
renal impairment, and not allergic to iodinated contrast medium). 
We chose to exclude the costs and benefits related to periods after 
the diagnosis phase (such as costs of medication, revascularization, 
hospitalization, and possible gains in QALY) in the model because 
they entail greater complexity and uncertainty. However, there is 
evidence that the diagnosis of obstructive CAD (vs. false-negative 
tests) is associated with an increase of three QALYs over a period 
of 10 years3. Depending on the assumptions made, it is possible 
that long-term analysis produces results that are significantly 
different from those obtained in this analysis. In addition, to avoid 
a more complex analysis, not all possible diagnostic strategies 
were considered; we chose accessible and frequently utilized 
modalities and diagnostic procedures. Moreover, conclusive 
tests were classified as positive or negative, in a reductionist 
dichotomization which is inevitable in this type of analysis. 
Finally, cost-effectiveness should be one of the criteria considered 
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Table 5 – Incremental cost-effectiveness of diagnostic strategies in hypothetical cohorts of 100 patients with a PLD of 10%–60%, considering 
identical prices for MPS and CCTA of the coronary arteries. For a PLD of ≥60%, all strategies were dominated by CATH
Pretest likelihood Diagnostic strategy Total cost (€) Number of correct diagnoses* False-negative tests* ICER**
10%
No test 18.180 90.0 10.0 -
ET-CCTA 24.473 97.2 2.8 €874
ET-MPS 26.013 96.4 3.6 Dominated
CACS-CCTA 27.975 99.1 0.9 €1.819
CCTA 35.585 99.8 0.2 €11.234
StressEcho 36.338 98.9 1.1 Dominated
MPS 38.522 98.7 1.3 Dominated
CATH 59.877 100 0 €121.461
20%
ET-CCTA 34.349 94.4 5.6 -
CACS-CCTA 34.974 98.2 1.8 €162
TET-MPS 36.766 92.8 7.2 Dominated
CCTA 40.918 99.6 0.4 €4.388
StressEcho 41.862 97.7 2.3 Dominated
MPS 44.957 97.4 2.6 Dominated
CATH 59.877 100 0 €47.397
30%
CACS-CCTA 41.973 97.4 2.6 -
ET-CCTA 44.224 91.6 8.4 Dominated
CCTA 46.252 99.4 0.6 €2.106
StressEcho 47.386 96.6 3.4 Dominated
ET-MPS 47.519 89.2 10.8 Dominated
MPS 51.392 96.1 3.9 Dominated
CATH 59.877 100 0 €22.709
40%
CACS-CCTA 48.972 96.5 3.5 -
CCTA 51.585 99.2 0.8 €964
StressEcho 52.910 95.4 4.6 Dominated
ET-CCTA 54.099 88.8 11.2 Dominated
MPS 57.827 94.8 5.2 Dominated
ET-MPS 58.272 85.6 14.4 Dominated
CATH 59.877 100 0 €10.365
50%
CACS-CCTA 55.971 95.6 4.4 -
CCTA 56.919 99.0 1.0 €280
StressEcho 58.434 94.3 6.7 Dominated
CATH 59.877 100 0 €2.959
ET-CCTA 63.975 86.0 14.0 Dominated
MPS 64.262 93.5 6.5 Dominated
ET-MPS 69.025 82.0 18.0 Dominated
60%
CATH 59.877 100 0 -
CCTA 62.252 98.8 1.9 Dominated
CACS-CCTA 62.970 94.7 5.3 Dominated
StressEcho 63.958 93.1 6.9 Dominated
MPS 70.697 92.2 7.8 Dominated
ET-CCTA 73.850 83.2 16.8 Dominated
ET-MPS 79.778 78.3 21.7 Dominated
* At the end of the diagnostic strategy, i.e., including the results of CATH when the noninvasive tests are positive or inconclusive. ** Incremental cost per additional 
correct diagnosis. ICER: incremental cost-effectiveness ratio (∆ cost/∆ correct diagnosis), ET: ergometric test, CCTA: computed tomography angiography of the coronary 
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Table 6 – Incremental cost-effectiveness of diagnostic strategies in hypothetical cohorts of 100 patients with a PLD of 10%–90%. considering 
zero cost for false-negative tests. The dominated strategies are not shown
Pretest likelihood Diagnostic strategy Total cost (€) Number of correct diagnoses* False-negative tests* ICER** (€)
10%
ET-CCTA 19.378 97.2 2.8 -
CACS-CCTA 26.379 99.1 0.9 3.637
CCTA 35.221 99.8 0.2 13.052
CATH 59.877 100 0 123.279
20%
ET-CCTA 24.157 94.4 5.6 -
CACS-CCTA 31.783 98.2 1.8 1.980
CCTA 40.191 99.6 0.4 6.206
CATH 59.877 100 0 49.215
30%
ET-CCTA 28.937 91.6 8.4 -
CACS-CCTA 37.187 97.4 2.6 1.428
CCTA 45.161 99.4 0.6 3.924
CATH €59.877 100 0 24.527
40%
ET-CCTA 33.717 88.8 11.2 -
CACS-CCTA 42.591 96.5 3.5 1.152
CCTA 50.131 99.2 0.8 2.782
CATH 59.877 100 0 12.183
50%
ET-CCTA 38.496 86.0 14.0 -
CACS-CCTA 47.995 95.6 4.4 987
CCTA 55.101 99.0 1.0 2.098
CATH 59.877 100 0 4.777
60%
ET-CCTA 37.581 83.4 16.6 -
StressEcho 51.435 93.1 6.9 822
CACS-CCTA 53.399 94.7 5.3 1.210
CATH 59.877 100 0 1.231
70%
ET-CCTA 48.059 80.4 19.6 -
StressEcho 54.872 92.0 8.0 588
CATH 59.877 100 0 623
80%
ET-CCTA 52.836 77.6 22.4 -
CATH 59.877 100 0 314
90%
ET-CCTA 57.615 74.8 25.2 -
CATH 59.877 100 0 90
* At the end of the diagnostic strategy. i.e.. including the results of CATH when the noninvasive tests are positive or inconclusive. ** Incremental cost per additional 
correct diagnosis. ICER: incremental cost-effectiveness ratio (∆ cost/∆ correct diagnosis). ET: ergometric test. CCTA: computed tomography angiography of the coronary 
arteries. CaSc: calcium scoring. MPS: myocardial perfusion scintigraphy. StresEco: stress echocardiogram with dobutamine
related factors (availability, experience, etc.) should be considered 
during the selection of a complementary diagnosis method.
Conclusions
The diagnostic algorithms that include cardiac CCTA are 
the most cost-effective in symptomatic patients with suspected 
stable coronary disease and a PLD of ≤50%. In these patients, 
depending on the PLD and the willingness to pay per correct 
diagnosis, CCTA may be used as a first-line test or reserved for 
patients with positive/inconclusive ergometric test results or CaSC 
> 0. In high-risk patients (PLD ≥ 60%), immediate CATH appears 
to be the most cost-effective strategy. For all PLDs, strategies based 
on ischemia tests appear to be more expensive and less effective 
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